Favorite mid-cap biotech with the most upside? (500M–2.5B mkt cap)

Looking for biotech ideas in a specific sweet spot: market cap over 500M but under 2.5B.

These are some I have in mind right now:
OCS, RGNX, FDMT, IMRX, PRAX, RARE, SLNO, SLDB​

For anyone who follows this space:

• Which of these do you think are the best setup right now in terms of risk/reward and upside over the next few years?
• Any you would avoid completely and why?
• If you have other biotech names in the 500M–2.5B market-cap range you like more, drop your top 1–3 and the key catalyst (trial readout, FDA decision, partnership, etc.).